Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817278 | 0.83 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL561353 | 0.78 | GAA (0.59) | GAANPSR1ATMMEN1KMT2A | |
| Water SCHEMBL3423431 | 0.77 | GAA (0.57) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL896346 | 0.77 | GAA (0.57) | GAANPSR1ATMMEN1KMT2A | |
| Water SCHEMBL3423432 | 0.75 | GAA (0.56) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL25392565 | 0.75 | KMT2A (0.37) | NPSR1ATMKMT2A | |
| SCHEMBL14586465 | 0.72 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL13049649 | 0.72 | GAA (0.65) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL896479 | 0.70 | GAA (1.00) | GAANPSR1ATMMEN1KMT2A | |
| SCHEMBL18380993 | 0.70 | GAA (0.62) | GAANPSR1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119384415-A | CD73 compounds | 吉利德科学公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-1582250-B1 | Absorbent with improved oxidation resistance and process for deacidifying fluid fluxes | BASF SE (DE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-7666813-B2 | an aliphatic amine, in particular an alkanolamine, and a non-hydroquinoid antioxidant for removal of CO2, H2S, SO2, CS2, HCN, COS, disulfides or mercaptans as impurities in reaction gases formed in the oxidation of organic materials to prevent the emission of above gases | BASF AKTIENGESELLSCHAFT (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1582250-A2 | Absorbent with improved ocidation resistance and process for deacidifying fluid fluxes | BASF AKTIENGESELLSCHAFT (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050202967-A1 | an aliphatic amine, in particular an alkanolamine, and a non-hydroquinoid antioxidant for removal of CO2, H2S, SO2, CS2, HCN, COS, disulfides or mercaptans as impurities in reaction gases formed in the oxidation of organic materials to prevent the emission of above gases | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | GAA 67/4885NPSR1 1633/4885ATM 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.